TP53 and cancer: While searching for small molecules targeting p53 (16–18), we identified a category of small molecules including quinacrine that induced substantial high levels of DR5 and enhanced TRAIL sensitivity or reversed TRAIL resistance in almost all cancer cell lines tested (16, 17, 19).